CA3047159A1 - Thrombin inhibitors for treatment of stroke and related coagulative disorders - Google Patents

Thrombin inhibitors for treatment of stroke and related coagulative disorders Download PDF

Info

Publication number
CA3047159A1
CA3047159A1 CA3047159A CA3047159A CA3047159A1 CA 3047159 A1 CA3047159 A1 CA 3047159A1 CA 3047159 A CA3047159 A CA 3047159A CA 3047159 A CA3047159 A CA 3047159A CA 3047159 A1 CA3047159 A1 CA 3047159A1
Authority
CA
Canada
Prior art keywords
thrombin
peptide
seq
inhibitor
exosite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3047159A
Other languages
English (en)
French (fr)
Inventor
Richard J. Payne
Shaun Phillip Jackson
Pedro Jose BARBOSA PEREIRA
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905231A external-priority patent/AU2016905231A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of CA3047159A1 publication Critical patent/CA3047159A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3047159A 2016-12-16 2017-12-15 Thrombin inhibitors for treatment of stroke and related coagulative disorders Pending CA3047159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905231A AU2016905231A0 (en) 2016-12-16 Thrombin inhibitors for treatment of stroke and related coagulative disorders
AU2016905231 2016-12-16
PCT/AU2017/051405 WO2018107247A1 (en) 2016-12-16 2017-12-15 Thrombin inhibitors for treatment of stroke and related coagulative disorders

Publications (1)

Publication Number Publication Date
CA3047159A1 true CA3047159A1 (en) 2018-06-21

Family

ID=62557849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3047159A Pending CA3047159A1 (en) 2016-12-16 2017-12-15 Thrombin inhibitors for treatment of stroke and related coagulative disorders

Country Status (8)

Country Link
US (1) US11091535B2 (https=)
EP (1) EP3555116A4 (https=)
JP (2) JP2020501561A (https=)
CN (1) CN110139871A (https=)
AU (1) AU2017376839B2 (https=)
CA (1) CA3047159A1 (https=)
NZ (1) NZ754781A (https=)
WO (1) WO2018107247A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590911B (zh) * 2019-09-30 2021-10-22 华南理工大学 一种含酪氨酸硫酸化修饰的多肽合成方法及其应用
CN114887123B (zh) * 2022-04-18 2023-07-04 南通大学 水蛭素接枝纳米纤维血管支架材料、制备方法与应用
CN119462906A (zh) * 2024-11-11 2025-02-18 武汉元启合生科技有限公司 一种酪氨酸硫酸化的重组水蛭素、制备方法及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4323754C1 (de) 1993-07-15 1994-12-01 Gruenenthal Gmbh Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
US6759384B1 (en) * 1994-04-26 2004-07-06 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
WO2001000667A2 (en) * 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
CA2394803A1 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Novel human protein kinases and protein kinase-like enzymes
EP1425296B1 (de) * 2001-09-10 2011-04-13 Novel Science International GmbH Organische verbindungen mit biologischer wirkung als thrombinhemmer und ihre verwendung
JP3648548B2 (ja) * 2001-10-15 2005-05-18 国立大学法人三重大学 血液凝固阻害活性を有するハマダラカ由来のＡｓ−１蛋白質
DE10301255A1 (de) 2003-01-15 2004-07-29 Cpi Creative Pharma International Gmbh Organische Verbindungen mit biologischer Wirkung als Thrombinhemmer und ihre Verwendung
JP2008532490A (ja) * 2005-02-15 2008-08-21 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
CN100595208C (zh) * 2006-07-31 2010-03-24 浙江中医药大学 硫酸化丝素蛋白的制备方法及其在抗凝血药物上的应用
GB0711779D0 (en) * 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
WO2014194015A1 (en) * 2013-05-30 2014-12-04 Virginia Commonwealth University Sulfated beta-o4 low molecular weight lignins
WO2014194361A1 (en) * 2013-06-04 2014-12-11 The University Of Sydney Peptide ligation
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
JP2023529993A (ja) * 2020-06-19 2023-07-12 ザ・ユニバーシティ・オブ・シドニー 血栓塞栓状態の治療のための改良されたトロンビン阻害剤

Also Published As

Publication number Publication date
WO2018107247A1 (en) 2018-06-21
AU2017376839A1 (en) 2019-07-11
JP2022130527A (ja) 2022-09-06
US11091535B2 (en) 2021-08-17
US20190367583A1 (en) 2019-12-05
EP3555116A4 (en) 2020-07-22
NZ754781A (en) 2021-12-24
JP2020501561A (ja) 2020-01-23
EP3555116A1 (en) 2019-10-23
CN110139871A (zh) 2019-08-16
AU2017376839B2 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
KR100665490B1 (ko) 인자 Ⅶａ 억제제
JPH08509735A (ja) トロンビン阻害剤
JP2022130527A (ja) 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤
EP0802986B1 (en) Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods
KR20110031280A (ko) 펩티드, 펩티드모방체 및 그 유도체, 그 제조 방법 및 치료적 및/또는 예방적 활성 약학적 조성물의 제조를 위한 그들의 용도
JP2000509993A (ja) アポリポタンパク質ｂ―１００由来の抗凝血性ペプチド断片
CZ334095A3 (en) Compounds containing chains of amino acids, their use and pharmaceutical compositions containing thereof
ES2539284T3 (es) Procedimiento de producción de VWF maduro a partir del propéptido de VWF
US20230416341A1 (en) Improved thrombin inhibitors for treatment of thromboembolic conditions
Class et al. Patent application title: THROMBIN INHIBITORS FOR TREATMENT OF STROKE AND RELATED COAGULATIVE DISORDERS
US5837684A (en) Peptides
PT1157040E (pt) Derivados peptídicos de baixo peso moleculatr como inibidores da interacção laminina/nidogénio
CN102124026A (zh) 肽及其衍生物、其制备及其在制备治疗性和/或预防性的活性药物组合物中的用途
CA2610496A1 (en) Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
EP4685154A1 (en) Polypeptide derived from tridegin
Maxwell et al. Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms
US6797806B2 (en) Fragments of CR1 and their use
EP2274330A1 (en) Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
JPH09503221A (ja) 血液凝固のカスケードにおいて治療上活性である新規ペプチド誘導体、その製造方法、及びそれらを含有する医薬組成物
AU691814C (en) Factor VII-derived peptides
WO2026006882A1 (en) Inhibitors of fxia
JPH07258280A (ja) リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202